Vitamin D, Thyroid Hormones and Cardiovascular Risk: Exploring the Components of This Novel Disease Triangle

Cristina Vassalle1*, Alessandra Parlanti1, Alessandro Pingitore2, Sergio Berti1, Giorgio Iervasi2 and Laura Sabatino2

1 Fondazione CNR-Regione Toscana Gabriele Monasterio, Pisa, Italy, 2 Institute of Clinical Physiology, CNR, Pisa, Italy

The role of thyroid hormones (THs) in the cardiovascular (CV) system, through several direct and indirect effects is recognized. Even very small modification in TH levels (as those observed in subclinical hypothyroidism or hyperthyroidism, and low triiodothyronine syndrome) may adversely affect the CV system, whereas thyroid hormones benefit the CV system and improve the prognosis. There is also evidence of vitamin D effects on cardiometabolic disease (e.g., through modulation of endothelial and smooth muscle cell activity, renin-angiotensin-aldosterone system, nitric oxide, oxidative stress, and inflammatory response), as well as an association between vitamin D [25(OH)D] deficiency and autoimmune thyroid diseases or cancer, and a relationship between vitamin D concentration and titers of antibodies and thyroid autoimmunity replacement. Interestingly, experimental data indicate a direct effect of vitamin D on Type 2 deiodinase expression causing subsequential peripheral conversion of T4 into T3. However, the functional links among THs, vitamin D and the cardiovascular system, and clinical effects of coexisting abnormalities in this new troublesome triad, have not yet been reviewed. The main aim of this review is to discuss pathophysiology of this relationship, proposing new mechanistic insights involving vitamin D in the modulation of cardiometabolic disease and thyroid profile.

Keywords: vitamin D, 25(OH)D, thyroid hormones, cardiovascular system, pathophysiology

INTRODUCTION

The roles of thyroid hormones (THs) in cardiovascular (CV) disease, such as heart failure (HF) or acute myocardial infarction (MI), through several direct and indirect effects are well-known (Jabbar et al., 2017; Abdel-Moneim et al., 2020). The two conditions share a number of underlying mechanisms and risk factors (e.g., endothelial dysfunction, increased blood pressure and dyslipidemia) (Jabbar et al., 2017). Moreover, the importance of THs in CV homeostasis may be deduced by the fact that even very small changes in TH levels (e.g., those observed in subclinical hypothyroidism or hyperthyroidism, and low triiodothyronine syndrome) adversely impact the CV system, whereas THs benefit the CV system and improve the prognosis (Razvi et al., 2018; Mastorci et al., 2020). Moreover, whether experimental studies suggest that TH administration may reduce
indicates that the manifestations of subtle thyroid abnormalities (e.g., low T3 syndrome) during AMI course are associated with adverse prognosis (Razvi et al., 2018).

In this context, the classical roles of vitamin D are related to the regulation of bone turnover and phospho-calcium homeostasis (Caprio et al., 2017). However, the pleiotropic roles of vitamin D have been recognized through preclinical and observational studies, and the importance of vitamin D in non-skeletal sites has emerged, as well as the role of vitamin D in type 2 diabetes (T2D) and cardiovascular and autoimmune diseases, neoplasia, and all-cause mortality (Caprio et al., 2017). Many data indicate that Vitamin D affects cardiometabolic disease. Its actions include modulation of endothelial and smooth muscle cell activity, renin-angiotensin-aldosterone system (RAAS), insulin, nitric oxide, oxidative stress status, inflammatory response, as well as aortic valve calcification processes (Kim et al., 2017; Latic and Erben, 2020; de la Guía-Galípienso et al., 2020). Its deficiency has been associated with CV risk, a higher risk of atherosclerosis, HF and CV mortality (Latic and Erben, 2020; de la Guía-Galípienso et al., 2020).

Moreover, there are some evidence suggesting an association between vitamin D [25(OH)D, the form by which vitamin D is measured in blood] deficiency and autoimmune thyroid diseases (e.g., Hashimoto’s thyroiditis and Graves’ disease, and/or postpartum thyroiditis), and a relationship between Vitamin D levels and titers of antibodies and thyroid autoimmunity replacement (Kim, 2017). Experimental results suggest that vitamin D status could exert a role on thyroid cancer onset and progression, and that the active form of vitamin D [1,25(OH)2D3] might be beneficial in thyroid cancer treatment (Kim, 2017). Interestingly, vitamin D has been shown to be associated with an increase of Type 2 deiodinase (DIO2) levels and peripheral conversion of THs (specifically from thyroxine-T4 into triiodothyronine-T3) in tissue homogenates from liver, kidney, muscle, femur bone, heart and brain of diabetic rats (Alrefaie and Awad, 2015). Moreover, although all the mechanisms underlying the role of vitamin D on TH profile are not completely understood, likely there may be the involvement of vitamin D-related antioxidants, anti-inflammatory and immunoregulatory effects (Kim, 2017).

The functional links among THs, vitamin D and the cardiovascular system, and clinical effects of coexisting abnormalities in this new troublesome triad, have not yet been reviewed. The main aim of this review is to discuss pathophysiology of this triangle, proposing new mechanistic insights involving vitamin D in the onset and development of cardiometabolic disease and TH function.

**THs AND CV SYSTEM**

TH system has a central regulatory role on virtually all metabolic functions in the human body by interacting with several cellular pathways, TH facilitate the functional integration among different organs and systems, in various physiological and pathological conditions, involving autonomic nervous system, the renin-angiotensin-aldosterone system, vascular reactivity and renal function (Razvi et al., 2018). At CV level, TH regulate homeostasis mainly by influencing cardiac contractility and systemic vascular resistance. In chronic diseases, at systemic level, TH promote regenerative and reparative processes to compensate the systemic stress conditions (Sabatino et al., 2014). In this perspective, TH play as multiple level regulators and, thus, have a relevant potential for innovative therapeutic approaches (Pantos et al., 2007b, 2010). T3 is considered the biologically active form of TH and mediates almost all TH effects at tissue level. T3 is generated by 5-monodeiodination of T4 in peripheral tissues by type I (DIO1) and DIO2 deiodinases. A third enzyme, called type III 5-monodeiodinase (DIO3) is responsible of TH catabolism and catalyzes the removal of one iodine from the inner tyrosilic ring of T4 and its conversion to the inactive rT3 (reverse-T3) (Bianco and da Conceicao, 2018). THs homeostasis in the heart requires a fine regulation, involving specific transporters at plasma membranes (such as the monocarboxylate transporters MCT8 and MCT10) (Friesema et al., 2008). The finding of monodeiodinases activities in normal and pathological myocytes unveiled a more complex TH regulatory dynamic than initially thought, since it suggested that both hormones (not only the active T3) can be uploaded inside the cardiac cells by membrane transporters (Sabatino et al., 2000; Gereben et al., 2008). THs effects at genomic level are mediated by specific receptors (TRs): TRα (TRα1, TRα2), TRβ (TRβ1, TRβ2): TH-TR complex specifically interacts with TH-response elements (TREs) in the promoters of target genes (Cheng et al., 2010). Differently, the non-genomic action of TH trigger specific metabolic pathways involving receptors at plasma membrane level (i.e., integrin αvβ3) or cytosolic TRs (Pantos and Mourouzis, 2014). Recently, the protective effects of THs have been investigated in rats where the alteration of molecular function and biological processes turned out to be beneficial after MI (Pantos et al., 2007a). THs has been shown to increase cardiac contractility, stimulate cardiac hypertrophy and angiogenesis, reduce apoptosis, improve left ventricular remodeling and function. More specifically, T3 regulates myocardial contraction/relaxation in MI by inducing the pathological switch of myosin heavy chains (MHC) from α to β isoform, and controls calcium ions (Ca2+) flux into the sarcoplasmatic reticulum by inducing expression of sarcoplasmatic reticulum calcium adenosine triphosphatase (SERCA2) and inhibiting phospholamban (PLB), SERCA’s counteracting molecule (Kinugawa et al., 2001). Interestingly, the overexpression of TRα1 during the pathological hypertrophy settlement in MI in rats is strictly associated to this receptor redistribution from nucleus to cytoplasm, where it plays an important role in the (MHC) from α to β isoform switch (Kinugawa et al., 2001).

Besides the effects on the heart, TH genomic and, mainly, non-genomic effects are also evident on the vasculature, both in vascular smooth muscle (VSMC) and endothelial cells (Ojamaa et al., 1996; Sabatino et al., 2015). The rapidity with which VSMC respond to T3 suggest the
involvement of main non-genomic mechanisms, since the
genomic would require a longer period for protein synthesis
and for biological effects to be observed (Ojamaa et al.,
1996). It is well known that T3 induces vascular relaxation
via endothelium-dependent pathways. However, more recently,
several studies have demonstrated that T3 may potentiate
vascular relaxation also through endothelium-independent
mechanisms, in which VSMC are a crucial target for T3-mediated
vasodilatation (Samuel et al., 2017). More specifically, nitric
oxide (NO) production by VSMC, other than by endothelium,
has been considered the driving factor in local regulation
of vascular response (Lee et al., 2008) mainly via PI3K/Akt
signaling pathway activation (Carrillo-Sepúlveda et al., 2010).
Furthermore, it has been observed that both T4 and T3
administration induce new blood vessel formation via surface
receptor ανβ3-mediated pathway in human microvascular
endothelial cells (Balzan et al., 2013; Liu et al., 2014) and in rat
heart and aorta tissues during ischemic reperfusion procedure
(Sabatino et al., 2016).

VITAMIN D AND CV PATHOPHYSIOLOGY

Vitamin D receptors are present in a variety of cells and
tissues, including cardiomyocytes, VSMC and endothelial cells,
suggesting many extra-skeletal effects of this vitamin, over
the traditional calcium and phosphorus homeostasis (Gouni-
Berthold and Berthold, 2021). Indeed, several data reported
a correlation between vitamin D deficiency and CV disease,
as 25(OH)D levels appeared associated with different CV risk
factors (e.g., blood pressure, obesity, and metabolic syndrome),
iccidence of atherosclerosis and heart failure, peripheral arterial
disease, and adverse prognosis and mortality, suggesting that
the indirect association between hypovitaminosis D with the
cardiovascular system is essentially explained through its
association with cardiometabolic risk factors (Vassalle et al.,
2015). In particular, the effects of vitamin D on diabetes include
improvement of insulin sensitivity (e.g., through modulation of
adiponectin gene), increase of insulin gene transcription, insulin
receptor expression, and glucose transport (Maestro et al., 2000;
Lahbib et al., 2015; Lontchi-Yimagou et al., 2020). In humans,
25(OH)D inversely correlates with glycated hemoglobin, and
with prevalence and risk of diabetes (Zhao et al., 2020; Bejar et al.,
2021; Salih et al., 2021).

Over the course of time, it has been estimated that calcitriol
directly or indirectly regulates a myriad of genes, modulating
a number of pathophysiological pathways. Both genomic and
non-genomic actions are mediated by the vitamin D receptor
(VDR), through regulation of transcriptional activity of target
genes or activation of intracellular second messengers (Pike et al.,
2016). Nonetheless, the modulation of gene expression may be
regulated by co-regulatory elements rather than only by VDR
(Pike et al., 2016). Thus, it is difficult to list all possible effects
mediated by vitamin D on the CV system. In fact, many possible
mechanisms may explain effects of vitamin D on CV systems
through effects on endothelium (e.g., vitamin D deficiency causes
reduced eNOS expression and SOD activity), smooth muscle cells
and vascular calcification (e.g., modulating metalloproteinase
expression), RAAS activation, effects on altered inflammatory
pathways (e.g., vitamin D deficiency is associate with increased of
NF-kB and IL-6), insulin secretion and sensitivity (e.g., reducing
inflammation and oxidative stress, and regulates Ca2+ level in
different cellular types as well as adipokines release such as
adiponectin and leptin), parathyroid hormone (PTH) secretion
[1,25(OH)2D regulates its own synthesis decreasing the PTH
synthesis and secretion] (Jablonski et al., 2011; Aoshima et al.,
2012; Szeto et al., 2012; Vassalle and Pérez-López, 2013; Wacker
and Holiack, 2013; Lim et al., 2020; Szymbczak-Pajor et al., 2020;
Wee et al., 2021) (Figure 1).

Chronic vitamin D deficiency may predispose to
hypertension, and one mechanism recently identified
characterizing this direct cardiac effects is the modulation of
the function of transient receptor potential C cation channels,
which is a mechanosensitive cation channel that plays a role
in cardiac slow-force responses to hemodynamic changes
(Stratford et al., 2021). Moreover, vitamin D has direct effects
on the atrial electrophysiology and atrial fibrillation, a direct
association with regulation of cardiac autonomic activity,
and a direct role in the regulation of vasomotor inducing
changes of pressor and depressor vasomotor responses (Mann
et al., 2013; Hanafy et al., 2014). Some studies evidenced that
vitamin D deficiency results in structural and ionic channel
remodeling and autonomic dysfunction that may predispose
the individuals to lethal cardiac arrhythmias and sudden
cardiac death (Drechsler et al., 2010; Deo et al., 2011; Mann
et al., 2013). In fact, vitamin D has direct effects on myocytes.
Vitamin D also affects cardiac contractility indirectly by
calcium metabolism and directly via vitamin D receptors-VDR
(Tishkoff et al., 2008).

For it concerns atherosclerosis, vitamin D can act in
several ways. For example, macrophages lacking VDR present
an increase in the uptake of cholesterol and this results in
cholesterol accumulating in the intracellular space, whereas
knockdown of VDR in endothelial cells leads to endothelial
cell activation (upregulation of VCAM-1, ICAM-1 and IL-
6, decreased peripheral blood mononuclear cell-PBMC rolling
velocity and increased PBMC rolling flux and adhesion to the
endothelial line) (Szeto et al., 2012; Bozic et al., 2015).

Interestingly, among direct effects, recent data suggest that
vitamin D maintains endothelial stability in vitro by enforcing
cell-cell interactions (Vila Cuenca et al., 2018).

However, although several studies have demonstrated
beneficial effects of vitamin D supplementation (versus placebo)
on CV clinical manifestation and risk factors, no clear benefit
of vitamin D administration for CV disease has been evidenced
in randomized controlled trials (Latic and Erben, 2020; Michos
et al., 2021).

Surely further work is needed to establish the protective role
of vitamin D in this setting, as controversial results may be
due to interference of possible confounding factors, such as
baseline 25(OH)D levels, dose, duration of supplementation,
season, as well as population characteristics (e.g., number of
subjects enrolled, heterogeneity of patients, time spent outdoors),
which may be considered in result interpretation.
Vitamin D and Thyroid Pathophysiology

The finding relative to homology between the vitamin D receptor (VDR) and the TH receptor dates back to the late 1980s (McDonnell et al., 1988). Few years later, the VDR expression on rat follicular thyroid cells was evidenced, suggesting a possible vitamin D role in thyroid pathophysiology (Berg et al., 1994). However, until today, most data that evaluated the role of vitamin D in thyroid illnesses are only in the context of autoimmunity and cancer (recently reviewed in Kim et al., 2017; Mele et al., 2020).

Autoimmune Thyroid Disease (AITD)

Hypovitaminosis D appears involved in the pathogenesis of autoimmune disease, where the most common autoimmune thyroid diseases are Hashimoto’s thyroiditis (HT) and Grave’s disease (GD).

Hashimoto’s thyroiditis (HT) is characterized by lymphocytic infiltration destroying the gland tissue, inflammation, and release of thyroid antibodies (TPOAb and TgAb), leading to hypothyroidism.

A meta-analysis [including 6/3 studies with continuous/dichotomous 25(OH)D levels] showed that HT patients had lower values compared to controls, and more likely have 25(OH)D deficiency (Wang et al., 2015). Moreover, data on the inverse correlation between vitamin D values with thyroid volume, and duration and severity of HT, and TH and thyroid antibody levels further reinforcing the idea that vitamin D deficiency might play a role in the risk, onset and development of HT (Muscoguri et al., 2016; Chao et al., 2020).

Interestingly, several polymorphisms in the VDR gene (e.g., the most common BsmI, FokI, TaqI, and Apal) have been studied in their association with HT risk (O’Grady et al., 2014; Giovinazzo et al., 2017; Wang et al., 2017). Although the results are controversial and far from definitive, these data suggested the genetically determined low vitamin D might be associated with an increased risk of developing HT.

All together these data suggested the possibility of the use of vitamin D supplementation against HT. Much still needs to be done in this context, because available data retain many pitfalls, as
the study populations are generally small, patients heterogeneous, there is variability of administration (e.g., dose and timing of supplementation), and many confounding factors may affect final results (e.g., age, gender, obesity, lifestyle, baseline vitamin D status, univocity of categories to define hypovitaminosis, season) are often neglected. Moreover, if values higher than 30 ng/mL (75 nmol/L) are considered optimal for bone and mineral homeostasis health, correct levels to lower the risk of autoimmune disease onset and progression are largely unknown (Holick et al., 2011). However, to testify to this possibility, reduction of TPOAb and TgAb levels after cholecalciferol supplementation was observed in patients with low vitamin D (Simsek et al., 2016; Krysiak et al., 2018; Wang et al., 2018).

Grave’s disease (GD) is characterized by the presence of gland infiltration by T lymphocytes, thyroid stimulating hormone (TSH) receptor autoantibodies (TRAb), goiter, and ophthalmopathy, and hyperthyroidism.

Two meta-analyses suggested that a low vitamin D status may increase the risk of GD (Wang et al., 2015; Xu et al., 2015). Moreover, there is data on the association between low vitamin D levels and the thyroid autoantibody titre in patients with Graves’ disease as well as the association of polymorphisms in the vitamin D receptor (VDR) gene in patients with GD (Unal et al., 2014; Zhang et al., 2015; Veneti et al., 2019; Plazińska et al., 2020).

For it concerns vitamin D supplementation, there are a few studies in the GD setting. In one study, GD patients treated with standard therapy combined with calcitriol [methimazole 30 mg/d supplemented with 1.5 micrograms α(OH)D3 for 24 weeks] showed a greater decrease in serum FT4 and FT3, although there were no differences in TRAb levels compared to those taking only methimazole (Kawakami-Tani et al., 1997). Interestingly, a recent study suggested that administration of cholecalciferol (1000–2000 IU/day) in GD patients with hypovitaminosis D, if not decrease the recurrence rate within one year, determines an earlier occurrence in the group of GD patients not taking cholecalciferol (Cho and Chung, 2020).

**Thyroid Cancer**

Vitamin D seems to play a critical role in thyroid cancer onset and progression, acting with effects on a number of cellular pathways, including apoptosis, cellular proliferation and differentiation, angiogenesis, oxidative stress and inflammatory response (Mele et al., 2020). However, despite the strong evidence observed in experimental models, clinical studies give more uncertain results (Mele et al., 2020). Nonetheless, two recent meta-analyses evidenced the association between low vitamin D levels and increased risk for thyroid cancer (Hu et al., 2018; Zhao et al., 2019). Instead, more unclear are the studies investigating the role of vitamin D supplementation in preventing thyroid cancer onset, which remain inconclusive (Zhang et al., 2013; O’Grady et al., 2014).

**Central and Peripheral Effects on Thyroid Function**

Little is known on the relationship between vitamin D to other thyroid dysfunction or disease. It has been observed that Vitamin D may affect FRTL-5 cells (thyroid cell line established from normal thyroid glands in rats) inhibiting TSH-stimulated adenyl cyclase activity, iodide uptake and cell growth (Berg et al., 1994). Moreover, vitamin D3 administration decreased TSH values toward normal in diabetic rats (52 ± 13, 70 ± 19, 57 ± 19 µIU/ml in control group, diabetic group and diabetic group treated with vitamin D3, respectively) (Alrefaie and Awad, 2015). Accordingly, an inverse correlation between 25(OH)D levels and TSH was observed in general human populations (Chailurkit et al., 2013; Barchetta et al., 2015).

A central effect of 1,25(OH)2 vitamin D3 has been observed in the receptor modulation (VDR) of TSH secretion by rat pituitary thyrotroph cells (Sar et al., 1980; Smith et al., 1989). In this context, experimental data suggested that vitamin D could increase TRH-induced TSH secretion by pituitary thyrotroph cells (D’Emden and Wark, 1987). Despite these effects, it is also possible that the inverse low TSH in the presence of a high vitamin D could be due, almost in part, to increased THs caused by the stimulatory effect of vitamin D on thyrocytes, and the consequent negative feedback control that the THs exert over the hypothalamus and anterior pituitary, thus controlling the release of both thyrotropin releasing hormone (TRH) and TSH (Dietrich et al., 2012; Veneti et al., 2019).

Interestingly, vitamin D administration improved TH profile in diabetic rats, increasing DIO2 (Alrefaie and Awad, 2015). This effect of vitamin treatment was also observed in bone extracts from mice skeleton, where DIO2 activity appeared increased by 2 to 3-fold, and in primary osteoblastic cells, where 1,25(OH)2D3 dose- and time-dependently induced the mRNA expression of DIO2 (Miura et al., 2002; Gouveia et al., 2005).

All together these data suggested how vitamin D may be important, acting at central level for pituitary gland function, also modulating DIO2 expression at thyroid and other organ levels and consequently affecting peripheral conversion of T4 into T3 (Figure 2).

However, if is true that vitamin D may affects thyroid pathophysiology, this relationship is likely reciprocal, although less is understood on the influence of THs on vitamin D metabolism. It is known that excess of THs stimulates bone resorption, increasing the blood values of calcium and phosphorus and suppressing PTH secretion whereas in hypothyroidism the bone turnover is decreased, the serum calcium concentration tends to be lower, and PTH secretion activated (Delitala et al., 2020; Hans and Levine, 2021). Accordingly, some data suggested that THs can affect vitamin D metabolism and, consequently, modulate the availability of its active form 1,25-(OH)2D3 (decreased in the serum of hyperthyroid patients and increased in the serum of untreated hypothyroid patients), which appeared normalized upon restoration of normal thyroid function (Bouillon et al., 1980).

**VITAMIN D IN THE RELATIONSHIP BETWEEN THYROID AND CV SYSTEM**

In GD patients, a significant reduction of pulse wave velocity (PWV, index of arterial stiffness, recognized as a CV risk
factor) was observed among vitamin D insufficient participants after cholecalciferol supplementation (70 µg/day-2800 IU for 9 months; Grove-Laugesen et al., 2019). Other results suggested a role for hypovitaminosis D through actions on visceral fat and insulin resistance in the interaction between THs and metabolic syndrome, with consequently increase of cardiometabolic risk (Verrusio et al., 2019). Moreover, an interaction between vitamin D, insulin resistance and thyroid profile dysfunction was observed in obese subjects, likely driven by systemic inflammation, where vitamin D deficiency represented the only factor associated with presence of HT in such patients (Răcătaianu et al., 2018).

Another study, conducted in independent factor associated with presence of HT in such inflammation, where vitamin D deficiency represented the only was observed in obese subjects, likely driven by systemic inflammation, where vitamin D deficiency represented the only factor associated with presence of HT in such patients (Răcătaianu et al., 2018). Thus, in this context, the possibility to use vitamin D supplementation (safe and very rarely toxic even at high doses) instead or in combination with TH treatment in acute MI settings may be of interest. We evidenced that there is a relationship between LT3 syndrome and hypovitaminosis D in acute MI patients (submitted data). In the same population, we observed that patients with low vitamin D (deficient and insufficient groups) showed a trend toward higher TSH levels in comparison to patients who had adequate or optimal levels of vitamin D (1.8 ± 1.8 versus 1.4 ± 1.0), finding particularly evident in those with a severe hypovitaminosis D (<10 ng/L), although without reaching significance values (likely the number of patients enrolled, n = 120, needs to be increased) (Table 1). Moreover, patients had higher TSH levels in the Spring-Winter period as opposed to the Autumn-Summer season, according to previous data consistently reporting a significant TSH increase in the colder periods (Table 1; Maes et al., 1997; Das et al., 2018). Higher TSH levels in colder seasons can be due, almost partially, to TSH hypersecretion in response to lower ambient temperature, lower peripheral metabolism and change in diet and physical activity (Danforth et al., 1979; Shinomiya et al., 2014; Louzada et al., 2014). However, we also observed an inverse seasonal trend for 25(OH)D and TSH, as previously reported (Table 1; Barchetta et al., 2015; Das et al., 2018). This fact may suggest that vitamin D may have a role in the modulation of TSH secretion, similarly to its regulatory role on other pituitary hormones (e.g., growth hormone; Esposito et al., 2019).

Notably, patients with a severe hypovitaminosis D [25(OH)D ≤ 10 ng/L] showed lowest fT3/fT4 levels (a TH index, which reflect deiodinase activity and conversion of T4 to T3), suggesting that this category of patients may require more attention and could benefit more from 25(OH)D supplementation (Figure 3). This fact is further confirmed by previous data, showing that stable coronary artery disease prevalence and severity (multivessel disease) was particularly higher in patients with severe hypovitaminosis D (<10 ng/ml).

In this context, the case of Low T3 Syndrome (LT3) after AMI is interesting for its clinical significance (Jabbar et al., 2017). LT3 syndrome is characterized by an isolated reduction of blood T3 concentration with normal T4 and TSH levels (Jabbar et al., 2017). This condition interests about 20% of acute MI patients, and it is associated with more severe clinical manifestations (left ventricular dysfunction, large MI, and inflammatory and stress responses), and adverse prognosis (rate of major cardiac events and a short- and long-term mortality) (Razvi et al., 2018). Changes in blood THs after acute MI may be the result of increased DIO3 activity and reduced DIO1 and DIO2 activities (Olivares et al., 2007; Van den Bergh, 2014). At present, the utility of TH therapy in the management of acute MI is evaluated in early-phase clinical trials for improvement of TH profile, although also looking after possible important adverse effects related to supraphysiological doses as adverse effects in the application of this treatment (Razvi et al., 2018). This, in face of different combination of THs and CV triad, with consequently increase of cardiometabolic risk (Jabbar et al., 2017). This condition interests about 20% of acute MI patients, and it is associated with more severe clinical manifestations (left ventricular dysfunction, large MI, and inflammatory and stress responses), and adverse prognosis (rate of major cardiac events and a short- and long-term mortality) (Razvi et al., 2018). Changes in blood THs after acute MI may be the result of increased DIO3 activity and reduced DIO1 and DIO2 activities (Olivares et al., 2007; Van den Bergh, 2014). At present, the utility of TH therapy in the management of acute MI is evaluated in early-phase clinical trials for improvement of TH profile, although also looking after possible important adverse effects related to supraphysiological doses as adverse effects in the application of this treatment (Razvi et al., 2018). Thus, in this context, the possibility to use vitamin D supplementation (safe and very rarely toxic even at high doses) instead or in combination with TH treatment in acute MI settings may be of interest. We evidenced that there is a relationship between LT3 syndrome and hypovitaminosis D in acute MI patients (submitted data). In the same population, we observed that patients with low vitamin D (deficient and insufficient groups) showed a trend toward higher TSH levels in comparison to patients who had adequate or optimal levels of vitamin D (1.8 ± 1.8 versus 1.4 ± 1.0), finding particularly evident in those with a severe hypovitaminosis D (<10 ng/L), although without reaching significance values (likely the number of patients enrolled, n = 120, needs to be increased) (Table 1). Moreover, patients had higher TSH levels in the Spring-Winter period as opposed to the Autumn-Summer season, according to previous data consistently reporting a significant TSH increase in the colder periods (Table 1; Maes et al., 1997; Das et al., 2018). Higher TSH levels in colder seasons can be due, almost partially, to TSH hypersecretion in response to lower ambient temperature, lower peripheral metabolism and change in diet and physical activity (Danforth et al., 1979; Shinomiya et al., 2014; Louzada et al., 2014). However, we also observed an inverse seasonal trend for 25(OH)D and TSH, as previously reported (Table 1; Barchetta et al., 2015; Das et al., 2018). This fact may suggest that vitamin D may have a role in the modulation of TSH secretion, similarly to its regulatory role on other pituitary hormones (e.g., growth hormone; Esposito et al., 2019).

Notably, patients with a severe hypovitaminosis D [25(OH)D ≤ 10 ng/L] showed lowest fT3/fT4 levels (a TH index, which reflect deiodinase activity and conversion of T4 to T3), suggesting that this category of patients may require more attention and could benefit more from 25(OH)D supplementation (Figure 3). This fact is further confirmed by previous data, showing that stable coronary artery disease prevalence and severity (multivessel disease) was particularly higher in patients with severe hypovitaminosis D (<10 ng/ml).
and as such not definitive and sometimes controversial (Charoenngam and Holick, 2020).

Moreover, for it concerns association between vitamin D and Sars-CoV-2 infection, emerging data indicate that severe vitamin D deficiency resulted more common in COVID-19 patients, playing a significant role in worsening the prognosis of these patients, suggesting vitamin D supplementation as a possible prophylactic and therapy in this setting (Grant et al., 2020; Brito et al., 2021; Campi et al., 2021; Güven and Gültekin, 2021). On this regard, a previous meta-analysis evidenced that vitamin D supplementation resulted safe and protective against acute respiratory tract infection, with patients with severely deficiency experienced the major benefit (Martineau et al., 2017). For COVID-19 patients, a dosage of 50,000 IU of vitamin D3 twice a week for the first week and the dose of 50,000 IU for the second and third week was suggested to reach and maintain levels above 40 ng/ml (Ebadi and Montano-Loza, 2020).

Interestingly, a small cohort observational study evidenced that combined oral doses of vitamin D (1000 IU), Mg (150 mg), and vitamin B12 (500 µg) was associated with a significant reduction in the proportion of COVID patients with clinical worsening (requiring oxygen support, intensive care support, or both) (Tan et al., 2020).

Interestingly, seen the adverse repercussions of Sars-CoV-2 infection on the cardiovascular system and thyroid function, whether the use of supplementation to maintain sufficient vitamin D levels may alleviate these conditions and their complications in COVID-19 patients remains to be better elucidated (Gorini et al., 2020; Kumari et al., 2020; Zhang et al., 2020; Ansari Ramandi et al., 2021).

CONCLUSION

For many years medicine has been developing into separate, specialized, almost independent branches. However, much evidence reveals significant connections between organs, until now considered as single entities, revealing a complex intermingled network with a common list of causes, or contributing factors for “different diseases,” attesting for shared cellular and molecular mechanisms for their etiology and progression. So, we must approach a more holistic view to better understand pathophysiology and improve care of our patients. Certainly, a lot of aspects are not clear. Currently, there is not enough strong evidence to support screening for vitamin D deficiency or vitamin D supplementation in thyroid profile and CV disease setting with the purpose of risk reduction, or improvement of these conditions. Several factors will be still considered in future studies, such as seasonal adjustment of vitamin D levels, and variable populations and definite reference 25(OH)D values for deficiency in extra-skeletal conditions, such as CV disease. Moreover, most studies are based on a single measurement of serum vitamin D levels, which may not be the best indicator of 25(OH)D over time. Nonetheless, even considering the deepening of these aspects, available evidence suggested a role of vitamin D in the relationship between THs

VITAMIN D AND INFECTIOUS AND OTHER IMMUNE-RELATED DISEASES

A relationship between 25-hydroxyvitamin D hypovitaminosis and increased risk of developing different immune-related conditions and infectious diseases has been observed, and recently reviewed (Charoenngam and Holick, 2020). In particular low 25(OH)D levels are associated to psoriasis, type 1 diabetes, multiple sclerosis, rheumatoid arthritis, tuberculosis, sepsis, respiratory infection, and also COVID-19 (Ponsonby et al., 2005; Megna et al., 2020; Cristelo et al., 2021; Jaimni et al., 2021; Wald et al., 2021; Chetty and Chetty, 2021).

From these observations, many attempts have been made to utilize vitamin D supplementation as a treatment or co-treatment in addition to traditional immunomodulatory drugs. Unfortunately, there are not yet shared protocols od 25(OH)D supplementation in the different conditions, also due to the many variables that take place [e.g., dose, route of administration, dietary interference, genetic individual characteristics, and age, body mass index, season and sunlight exposure, baseline levels of 25(OH)D, patient typology, and supplementation time, and type of outcome measurements]. Thus, available data are heterogeneous,
and cardiometabolic disease, providing vitamin D as a potential additional, effective, low-cost, easily available and safe tool to be evaluated in the clinical practice for multi-organ and multi-disease benefits.

METHODS

We have performed a search for articles in PubMed to identify pertinent literature, till 13 August 2021, with the Boolean operator “vitamin D,” “25(OH)D,” “thyroid,” “cardiovascular disease,” “supplementation,” “thyroid hormones,” with interposition of the Boolean operator “AND.”

REFERENCES

Abdel-Moneim, A., Gaber, A. M., Gouda, S., Osama, A., Othman, S. I., and Allam, G. (2020). Relationship of thyroid dysfunction with cardiovascular diseases: updated review on heart failure progression. Hormones 19, 301-309. doi: 10.1007/s42000-020-00208-8

Alrefaie, Z., and Awad, H. (2015). Effect of vitamin D3 on thyroid function and deiodinase 2 expression in diabetic rats. Arch. Physiol. Biochem. 121, 206-209. doi: 10.3109/13813455.2015.1107101

Ansari Ramandi, M. M., Yarmohammadi, H., Beikmohammadi, S., Hosseiny Fahimi, B. H., Hatami, F., Beydokhti, H., et al. (2021). Comparison of the cardiovascular presentations, complications and outcomes following different coronaviruses’ infection: A systematic review. J. Cardiovasc. Thoric. Res. 3, 92–101. doi: 10.34172/jctv.2021.29

Aoshima, Y., Mizobuchi, M., Ogata, H., Kumata, C., Nakazawa, A., Kondo, F., et al. (2012). Vitamin D receptor activators inhibit vascular smooth muscle cell mineralization induced by phosphate and TNF-a. Nephrol. Dial. Transplant. 27, 1800-1806. doi: 10.1093/ndt/gfr758

Balzan, S., Del Carratore, R., Nardulli, C., Sabatino, L., Lubrano, V., and Iervasi, G. (2013). The Stimulative Effect of T3 and T4 on Human Myocardial Endothelial Cell Proliferation, Migration and Angiogenesis. J. Clin. Exp. Cardiolog. 4:12.

Barchetta, I., Baroni, M. G., Leonetti, F., De Bernardinis, M., Bertoccini, L., Fontana, M., et al. (2015). TSH levels are associated with vitamin D status and seasonality in an adult population of euthyroid adults. Clin. Exp. Med. 15, 389-396. doi: 10.1007/s10238-014-0290-9

Bejar, C. A., Goyal, S., Afzal, S., Mangino, M., Zhou, A., van der Most, P. J., et al. (2021). A Bidirectional Mendelian Randomization Study to evaluate the causal role of reduced blood vitamin D levels with type 2 diabetes risk in South Asians and Europeans. Nutr. J. 20:71.

Berg, J. P., Liane, K. M., Bjerhvode, S. B., Bjerø, T., Torjesen, P. A., and Haug, E. (1994). Vitamin D receptor binding and biological effects of cholecalciferol analogues in rat thyroid cells. J. Steroid. Biochem. Mol. Biol. 40, 145–150. doi: 10.1016/0961-0766(94)90021-3

Bianco, A. C., and da Concieicao, R. R. (2018). The deiodinase trio and thyroid hormone metabolism during over nutrition. J. Clin. Med. 7, 1810. doi: 10.3390/jcm70901810

Bouillon, R., Muls, E., and De Moor, P. (1980). Influence of thyroid function on the serum concentration of 2,5-dihydroxyvitamin D3. J. Clin. Endocrinol. Metab. 51, 793–797. doi: 10.1210/jcem-51-3-793

Bojac, M., Alvež, Á. de Pablo, C., Sanchez-Niño, M. D., Ortiz, A., Dolcet, X., et al. (2015). Impaired Vitamin D Signaling in Endothelial Cell Leads to an Enhanced Leukocyte-Endothelium Interplay: Implications for Atherosclerosis Development. PLoS One 10:e0136863. doi: 10.1371/journal.pone.0136863

Brito, D. T. M., Ribeiro, L. H. C., Daltro, C. H. D. C., and Silva, R. B. (2021). Vitamin D and COVID-19 severity and related mortality: a prospective study in Italy. BMC Infect. Dis. 21:566.

Caprio, M., Infante, M., Calanchini, M., Mammì, C., and Fabbri, A. (2017). Vitamin D: not just the bone. Evidence for beneficial pleiotropic extraskeletal effects. Eur. J. Weight. Disord. 22, 27–41. doi: 10.1007/s40591-016-0312-6

Caprio, M., Infante, M., Calanchini, M., Mammì, C., and Fabbri, A. (2017). Vitamin D: not just the bone. Evidence for beneficial pleiotropic extraskeletal effects. Eur. J. Weight. Disord. 22, 27–41.

REFERENCES

AUTHOR CONTRIBUTIONS

CV conceived the manuscript and wrote the original draft. LS wrote the TH/CV part and took care of the graphical figure development. All authors read and approved the final version of the manuscript.
Gorini, F., Bianchi, F., and Iervasi, G. (2020). COVID-19 and Thyroid: Progress

Friesema, E. C. H., Jansen, J., Jachtenberg, J. W., Visser, W. E., Kester, M. H. A., and

Giovinazzo, S., Vicchio, T. M., Certo, R., Alibrandi, A., Palmieri, O., Campennì,

Gouveia, C. H., Christoffolete, M. A., Zaitune, C. R., Dora, J. M., Harney, J. W.,

Gouni-Berthold, I., and Berthold, H. K. (2021). Vitamin D and

Jablonski, K. L., Chonchol, M., Pierce, G. L., Walker, A. E., and Seals,

Hu, M. J., Zhang, Q., Liang, L., Wang, S. Y., Zheng, X. C., Zhou, M. M., et al.

Holick, M. F., Binkley, N. C., Bischoff-Ferrari, H. A., Gordon, C. M., Hanley, D. A.,

Hans, S. K., and Levine, S. N. (2021). Hypoparathyroidism. Treasure Island (FL):

Hans, K. S., and Levine, S. N. (2021). Hypoparathyroidism. Treasure Island (FL): StatPears Publishing.

Holick, M. F., Binkley, N. C., Bischoff-Ferrari, H. A., Gordon, C. M., Hanley, D. A.,

Heaney, R. P., et al. (2011). Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96, 1911–1930. doi: 10.1210/jc.2011-0385

Huang, D. A., Zhang, S. L., Gu, Y. H., Huang, J. H., et al. (2011). Electromechanical effects of 1,25-dihydroxyvitamin d with antiatrial fibrillation activities. J. Cardiovasc. Electrophysiol. 25, 317–323. doi: 10.1111/jce.12309

Hans, K. S., and Levine, S. N. (2021). Hypoparathyroidism. Treasure Island (FL): StatPears Publishing.

Holick, M. F., Binkley, N. C., Bischoff-Ferrari, H. A., Gordon, C. M., Hanley, D. A.,

Heaney, R. P., et al. (2011). Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96, 1911–1930. doi: 10.1210/jc.2011-0385

Huang, D. A., Zhang, S. L., Gu, Y. H., Huang, J. H., et al. (2011). Electromechanical effects of 1,25-dihydroxyvitamin d with antiatrial fibrillation activities. J. Cardiovasc. Electrophysiol. 25, 317–323. doi: 10.1111/jce.12309

Hans, K. S., and Levine, S. N. (2021). Hypoparathyroidism. Treasure Island (FL): StatPears Publishing.

Holick, M. F., Binkley, N. C., Bischoff-Ferrari, H. A., Gordon, C. M., Hanley, D. A.,

Heaney, R. P., et al. (2011). Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96, 1911–1930. doi: 10.1210/jc.2011-0385

Huang, D. A., Zhang, S. L., Gu, Y. H., Huang, J. H., et al. (2011). Electromechanical effects of 1,25-dihydroxyvitamin d with antiatrial fibrillation activities. J. Cardiovasc. Electrophysiol. 25, 317–323. doi: 10.1111/jce.12309

Hans, K. S., and Levine, S. N. (2021). Hypoparathyroidism. Treasure Island (FL): StatPears Publishing.

Holick, M. F., Binkley, N. C., Bischoff-Ferrari, H. A., Gordon, C. M., Hanley, D. A.,

Heaney, R. P., et al. (2011). Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96, 1911–1930. doi: 10.1210/jc.2011-0385

Huang, D. A., Zhang, S. L., Gu, Y. H., Huang, J. H., et al. (2011). Electromechanical effects of 1,25-dihydroxyvitamin d with antiatrial fibrillation activities. J. Cardiovasc. Electrophysiol. 25, 317–323. doi: 10.1111/jce.12309

Hans, K. S., and Levine, S. N. (2021). Hypoparathyroidism. Treasure Island (FL): StatPears Publishing.

Holick, M. F., Binkley, N. C., Bischoff-Ferrari, H. A., Gordon, C. M., Hanley, D. A.,

Heaney, R. P., et al. (2011). Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96, 1911–1930. doi: 10.1210/jc.2011-0385

Huang, D. A., Zhang, S. L., Gu, Y. H., Huang, J. H., et al. (2011). Electromechanical effects of 1,25-dihydroxyvitamin d with antiatrial fibrillation activities. J. Cardiovasc. Electrophysiol. 25, 317–323. doi: 10.1111/jce.12309

Hans, K. S., and Levine, S. N. (2021). Hypoparathyroidism. Treasure Island (FL): StatPears Publishing.

Holick, M. F., Binkley, N. C., Bischoff-Ferrari, H. A., Gordon, C. M., Hanley, D. A.,

Heaney, R. P., et al. (2011). Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96, 1911–1930. doi: 10.1210/jc.2011-0385

Huang, D. A., Zhang, S. L., Gu, Y. H., Huang, J. H., et al. (2011). Electromechanical effects of 1,25-dihydroxyvitamin d with antiatrial fibrillation activities. J. Cardiovasc. Electrophysiol. 25, 317–323. doi: 10.1111/jce.12309

Hans, K. S., and Levine, S. N. (2021). Hypoparathyroidism. Treasure Island (FL): StatPears Publishing.

Holick, M. F., Binkley, N. C., Bischoff-Ferrari, H. A., Gordon, C. M., Hanley, D. A.,

Heaney, R. P., et al. (2011). Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96, 1911–1930. doi: 10.1210/jc.2011-0385

Huang, D. A., Zhang, S. L., Gu, Y. H., Huang, J. H., et al. (2011). Electromechanical effects of 1,25-dihydroxyvitamin d with antiatrial fibrillation activities. J. Cardiovasc. Electrophysiol. 25, 317–323. doi: 10.1111/jce.12309

Hans, K. S., and Levine, S. N. (2021). Hypoparathyroidism. Treasure Island (FL): StatPears Publishing.
Michos, E. D., Cainzos-Achirica, M., Heravi, A. S., and Appel, L. J. (2021). Vitamin D, Calcium Supplements, and Implications for Cardiovascular Health: JACC Focus Seminar. *J. Am. Coll. Cardiol.*, 77, 437–449.

Miura, M., Tanaka, K., Komatsu, Y., Suda, M., Yasoda, A., Sakuma, Y., et al. (2002). A novel interaction between thyroid hormones and 1,25(OH)2(2D3) in osteoblast formation. *Biochem. Biophys. Res. Commun.* 291, 987–994. doi: 10.1006/bbrc.2002.6561

Musco, G., Mari, D., Prolo, S., Fatti, L. M., Cantone, M. C., Garagnani, P., et al. (2016). 25 Hydroxyvitamin D Deficiency and Its Relationship to Autoimmune Thyroid Disease in the Elderly. *Int. J. Environ. Res. Public Health* 13:850. doi: 10.3390/ijerph13090850

Nardin, M., Verdoia, M., Schaffer, A., Barbieri, L., Marino, P., De Luca, G., et al. (2016). Vitamin D status, diabetes mellitus and coronary artery disease in patients undergoing coronary angiography. *Atherosclerosis* 250, 114–119. doi: 10.1016/j.atherosclerosis.2016.05.019

O’Grady, T. J., Kitahara, C. M., DiRienzo, A. G., and Gates, M. A. (2014). The Effects of Vitamin D treatment on thyroid autoimmunity. *J. Res. Med. Sci.* 21:85. doi: 10.4103/1735-1995.192501

Smith, M. A., McHenry, C., Oslapas, R., Hofmann, C., Hessel, P., and Paloyan, E. (1989). Altered TSH levels associated with increased serum 1,25-dihydroxyvitamin D3: a possible link between thyroid and parathyroid disease. *Surgery* 106, 987–991.

Stratford, K., Haykal-Coates, N., Thompson, L., Farraj, A., and Hazari, M. (2021). Early-life persistent vitamin D deficiency-induced cardiovascular dysfunction in mice is mediated by transient receptor potential C channels. *J. Steroid. Biochem. Mol. Biol.* 206:105804. doi: 10.1016/j.jsbmb.2020.105804

Szeto, F. L., Readon, C. A., Yoon, D., Wang, Y., Wong, K. E., Chen, Y., et al. (2012). Vitamin D receptor signaling inhibits atherosclerosis in mice. *Mol. Endocrinol.* 26, 1091–1101. doi: 10.1210/me.2011-1329

Tishkoff, D. X., Nibbelink, K. A., Holmberg, K. H., Dandu, L., and Simpson, R. U. (2008). Functional vitamin D receptor (VDR) in the t-tubules of cardiac myocytes: VDR knockout cardiomyocyte contractility. *Endocrinology* 149, 538–564. doi: 10.1210/en.2007-0111

Unal, A. D., Tarcin, O., Parlildar, H., Cigerli, O., Eroglu, H., and Demirag, N. G. (2014). Vitamin D deficiency is related to thyroid antibodies in autoimmune thyroiditis. *Cent. Eur. J. Immunol.* 39, 493–497. doi: 10.5101/cejim.2014.47735

Venet, S., Anagnostis, P., Adamidou, F., Artzouchaltzi, A. M., Boboridis, K., and Kita, M. (2019). Association between vitamin D receptor gene polymorphisms and Graves’ disease: a systematic review and meta-analysis. *Endocrine* 58, 24–41. doi: 10.1007/s12020-019-01902-3

Vassalle, C., and Pérez-López, F. R. (2013). “The Importance of Some Analytical and Confounding Factors in Relation to Clinical Interpretation of Results,” in *The Biomarker Validation – Technological, Clinical and Commercial Aspect*, eds H. Seitz, S. Schumacher (Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA), 107–146. doi: 10.1002/9783527680658.ch7

Vassalle, C., and Perez-Lopez, F. R. (2013). “The Importance of Some Analytical and Confounding Factors in Relation to Clinical Interpretation of Results,” in *The Biomarker Validation – Technological, Clinical and Commercial Aspect*, eds H. Seitz, S. Schumacher (Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA), 107–146. doi: 10.1002/9783527680658.ch7

Sabatino, L., Iervasi, G., Ferrazzi, P., Francesconi, D., and Chopra, I. J. (2000). A study of iodothyronine 3′-monodeiodinase activities in normal and pathological tissues in man and their comparison with activities in rat tissues. *Life. Sci.* 68, 191–202. doi: 10.1016/S0024-3205(00)00929-2

Sabatino, L., Iervasi, G., and Pingitore, A. (2014). Thyroid hormone and heart failure: from myocardial protection to systemic regulation. *Expert. Rev. Cardiovasc. Ther.* 12, 1227–1236. doi: 10.1586/14779072.2014.957674

Sabatino, L., Kusmic, C., Nicolini, G., Amato, R., Casini, G., Iervasi, G., et al. (2016). T3 enhances Ang2 in rat aorta in mycardial I/R: comparison with left ventricle. *J. Mol. Endocrinol.* 57, 139–149. doi: 10.1530/JME-16-0118

Salih, Y. A., Rasool, M. T., Ahmed, I. H., and Mohammed, A. A. (2021). Impact of vitamin D level on glycosylated control in diabetes mellitus type 2 in Dukhun. *Ann. Med. Surg.* 64:102208. doi: 10.1016/j.amsu.2021.102208.
Verdoia, M., Schaffer, A., Sartori, C., Barbieri, L., Cassetti, E., Marino, P., et al. (2014). Vitamin D deficiency is independently associated with the extent of coronary artery disease. *Eur. J. Clin. Invest.* 44, 634–642. doi: 10.1111/eci.12281

Verrusio, W., Magro, V. M., Renzi, A., Casciaro, B., Andreozzi, P., and Cacciafesta, M. (2019). Thyroid hormones, metabolic syndrome and Vitamin D in middle-aged and older euthyroid subjects: a preliminary study. *Aging Clin. Exp. Res.* 31, 1337–1341. doi: 10.1007/s40520-018-1071-1

Vila Cuenca, M., Ferrantelli, E., Meinster, E., Poud, S. M., Kovačević, I., de Menezes, R. X., et al. (2018). Vitamin D Attenuates Endothelial Dysfunction in Uremic Rats and Maintains Human Endothelial Stability. *J. Am. Heart Assoc.* 7:e008776.

Wacker, M., and Holiack, M. F. (2013). Vitamin D-effects on skeletal and extraskeletal health and the need for supplementation. *Nutrients* 5, 111–148. doi: 10.3390/nu5010111

Wald, E. L., Badke, C. M., Hintz, L. K., Spevak, M., and Sanchez-Pinto, L. N. (2015). Meta-analysis of the association between vitamin D and autoimmune thyroid disease. *Nutrients* 7, 2485–2498. doi: 10.3390/nu7042485

Zhang, H., Liang, L., and Xie, Z. (2015). Low Vitamin D Status is Associated with Increased Thyrotropin-Receptor Antibody Titer in Graves Disease. *Endocr. Prat. 21,* 258–263. doi: 10.4158/ep14191.or

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Vassalle, Parlanti, Pingitore, Berti, Iervasi and Sabatino. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.